Quince Therapeutics (QNCX) Insider Trading & Ownership $1.58 -0.02 (-0.94%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Quince Therapeutics (NASDAQ:QNCX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.80%Number OfInsiders Buying(Last 3 Years)5Amount OfInsider Buying(Last 3 Years)$753.72KNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$1.83K Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Insider Buying and Selling by Quarter Quince Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/29/2024Dirk ThyeCEOBuy77,500$0.69$53,475.00 8/21/2024Brendan HannahCOOBuy30,845$0.63$19,432.35 8/20/2024Charles S RyanPresidentBuy48,387$0.65$31,451.55 8/19/2024Brendan HannahCOOBuy2,155$0.58$1,249.90 12/14/2023David LamondDirectorBuy22,627$1.04$23,532.08 12/12/2023David LamondDirectorBuy22,327$1.02$22,773.54 12/7/2023David LamondDirectorBuy19,123$1.01$19,314.23 12/5/2023David LamondDirectorBuy19,123$1.01$19,314.23 12/1/2023David LamondDirectorBuy14,378$0.94$13,515.32 11/29/2023David LamondDirectorBuy14,378$0.98$14,090.44 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/30/2023David LamondDirectorBuy41,026$1.31$53,744.06 8/17/2023David LamondDirectorBuy24,766$1.29$31,948.14 8/15/2023David LamondDirectorBuy107,886$1.32$142,409.52 8/10/2023Dirk ThyeCEOBuy88,000$1.26$110,880.00 8/8/2023Brendan HannahInsiderBuy71,762$1.22$87,549.64 8/8/2023Dirk ThyeCEOBuy80,000$1.24$99,200.00 8/8/2023Margaret McloughlinDirectorBuy8,000$1.23$9,840.00 3/6/2023Ted MonohonCAOSell1,871$0.98$1,833.58 (Data available from 1/1/2013 forward) QNCX Insider Trading Activity - Frequently Asked Questions Who is on Quince Therapeutics' Insider Roster? The list of insiders at Quince Therapeutics includes Brendan Hannah, Charles S Ryan, David Lamond, Dirk Thye, Margaret Mcloughlin, and Ted Monohon. Learn more on insiders at QNCX. What percentage of Quince Therapeutics stock is owned by insiders? 16.80% of Quince Therapeutics stock is owned by insiders. Learn more on QNCX's insider holdings. Which Quince Therapeutics insiders have been buying company stock? The following insiders have purchased QNCX shares in the last 24 months: Brendan Hannah ($20,682.25), Charles S Ryan ($31,451.55), David Lamond ($112,539.84), and Dirk Thye ($53,475.00). How much insider buying is happening at Quince Therapeutics? Insiders have purchased a total of 270,843 QNCX shares in the last 24 months for a total of $218,148.64 bought. Quince Therapeutics Key ExecutivesDr. Dirk Thye M.D. (Age 54)CEO, Chief Medical Officer & Director Compensation: $856.5kDr. Charles S. Ryan J.D. (Age 60)Ph.D., President Compensation: $524.47kMr. Brendan Hannah M.B.A. (Age 38)Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer Compensation: $607.5kDr. Guenter R. Janhofer M.D.Ph.D., Chief Scientific OfficerMs. Stacy RoughanVice President of Corporate Communications & Investor RelationsMs. Mary Ellen SillivosVice President of Human ResourcesDr. Stewart A. Low Ph.D.Head of Discovery More Insider Trading Tools from MarketBeat Related Companies CTMX Insider Transactions ALDX Insider Transactions BNTC Insider Transactions TNXP Insider Transactions FDMT Insider Transactions AMRN Insider Transactions CADL Insider Transactions CAPR Insider Transactions LRMR Insider Transactions DMAC Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Loop Industries Insiders Buy Stock, Signal Confidence in OutlookDueling Insider Moves: Heavy Buying Here, Big Selling ThereCostco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks This page (NASDAQ:QNCX) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
